The FDA has approved the selective alpha_1A-adrenergic receptor agonist oxymetazoline as a 1% cream (Rhofade – Allergan) for topical treatment of persistent facial erythema of rosacea in adults. Brimonidine, a selective alpha₂-adrenergic receptor agonist, was approved in 2013 as a 0.33% gel (Mirvaso) for the same indication.1 Like Mirvaso, Rhofade is not indicated for treatment of inflammatory lesions of rosacea. Oxymetazoline has been available over the counter for many years as a nasal decongestant spray (Afrin, and others).

TREATMENT OF ROSACEA — Rosacea is a common, chronic inflammatory facial condition of unknown cause characterized by erythema, telangiectasia, and/or acneiform lesions (papules and pustules), usually on the central part of the face. Avoidance of exposure to extremes of temperature, hot baths ... more       Show References Hide References

Would you like to read the rest of this article?  Gain access below.